The U.S. Food and Drug Administration approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved for patients with CLL whose cancer is no longer being controlled by other forms of chemotherapy. CLL primarily affects people older than 50 and arises from a group of white blood cells known as B-cells that are part of the body’s immune system.